Eli Lilly’s experimental oral GLP-1 receptor agonist, orforglipron, demonstrated up to 12.4% mean weight loss at 72 weeks in phase 3 trials involving adults with obesity or overweight status and at least one weight-related comorbidity. While meeting primary endpoints, the drug’s effectiveness falls short compared to injectable competitors like Novo Nordisk’s Wegovy and Lilly’s Zepbound, which showed 15% to 21% weight loss. Lilly plans regulatory submissions by year-end and explores combination uses and maintenance therapy options. The results confirm the oral drug’s potential yet highlight challenges in competing with existing injectable therapies.